Amgen Inc (NASDAQ:AMGN)

182.98
Delayed Data
As of 4:00pm ET
 -0.57 / -0.31%
Today’s Change
152.16
Today|||52-Week Range
201.23
+5.22%
Year-to-Date
Top Analyst Report for Amgen, TOTAL S.A. & Marriott
5:09pm / Zacks.com - Paid Partner Content
Roche's Rituxan Gets Priority Review for Label Expansion
Feb 14 / Zacks.com - Paid Partner Content
Minority Report
2:39pm / GuruFocus News - Paid Partner Content
Can ImmunoGen's Key Ovarian Cancer Candidate Drive Growth?
Feb 14 / Zacks.com - Paid Partner Content
Novartis Psoriasis Drug Cosentyx Positive in SCALP Study
9:03am / Zacks.com - Paid Partner Content
3 ETFs to Watch on Biotech Earnings
Feb 10 / Zacks.com - Paid Partner Content
Roche (RHHBY) to Acquire Flatiron Health for $1.9 Billion
Feb 16 / Zacks.com - Paid Partner Content
Novartis' Cosentyx Label Expanded to Include Scalp Psoriasis
Feb 08 / Zacks.com - Paid Partner Content
AbbVie Hikes Dividend by 35%, Launches $10B Buyback Plan
Feb 16 / Zacks.com - Paid Partner Content
Spectrum Pharma's Rolontis Positive in Pivotal Cancer Study
Feb 06 / Zacks.com - Paid Partner Content

Today’s Trading

Previous close183.55
Today’s open182.89
Day’s range182.14 - 184.31
Volume3,944,566
Average volume (3 months)3,218,589
Market cap$132.3B
Data as of 4:00pm ET, 02/20/2018

Growth & Valuation

Earnings growth (last year)-73.73%
Earnings growth (this year)+5.43%
Earnings growth (next 5 years)+4.98%
Revenue growth (last year)+0.45%
P/E ratio68.0
Price/Sales5.61
Price/Book5.25

Competitors

 Today’s
change
Today’s
% change
GILDGilead Sciences+0.24+0.30%
BIIBBiogen-4.42-1.51%
ILMNIllumina Inc-2.63-1.15%
----
Data as of 4:00pm ET, 02/20/2018

Financials

Next reporting dateApril 24, 2018
EPS forecast (this quarter)$3.20
Annual revenue (last year)$22.8B
Annual profit (last year)$2.0B
Net profit margin8.69%

Profile

Sector
Health Technology
Industry
Biotechnology
Chairman &
Chief Executive Officer
Robert A. Bradway
Executive Vice President-
Operations
Esteban Santos
Corporate headquarters
Thousand Oaks, California

Forecasts